Stereotactic ablative radiotherapy (SABR) after systemic antineoplastic treatment for patients with unresectable oligometastases (lung; liver; adrenal glands) from solid tumours: SARASTRO Trial (Stereotactic Ablative Radiotherapy After Systemic TReatment for Oligometastases) A randomised phase II trial - SABR after systemic treatment for oligometastases

niversitair Medisch Centrum Groningen0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Patients above age 18.
•- WHO-PS (performance status) 0 - 1.
•- Patients with unresectable metastases to lung, and/or liver, and/or one adrenal gland, who have received systemic therapy and show partial remission or stable disease.
•- Using RECIST 1.1 criteria (see the Appendix): Partial response or stable disease at restaging (compared with staging prior to last 4*6 cycles of chemotherapy). Note this exception: After bevacizumab-containing treatment, response of liver metastases should be assessed using CT-morphologic criteria as described by Chun et al., JAMA 2009;302:2338
•- Possibility to define target lesions that fulfil the following criteria:
•- No lesion larger than 4 cm;
•- Not more than 5 metastases >= 8 mm in total (lesions smaller than 8 mm in diameter are NOT counted and will NOT be irradiated);
•- Not more than 3 lesions >= 8 mm in the lung;
•- Not more than 3 lesions >= 8 mm in the liver;
•- If adrenal gland metastasis: only unilateral lesion;
•- primary tumour has been completely removed

发起方